Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Time to surgery and its impact on survival in patients with endometrial cancer: A National cancer database study.

AlHilli MM, Elson P, Rybicki L, Khorana AA, Rose PG.

Gynecol Oncol. 2019 Jun;153(3):511-516. doi: 10.1016/j.ygyno.2019.03.244. Epub 2019 Apr 15.

PMID:
31000472
2.

Perioperative adverse events in women undergoing concurrent urogynecologic and gynecologic oncology surgeries for suspected malignancy.

Davidson ERW, Woodburn K, AlHilli M, Ferrando CA.

Int Urogynecol J. 2018 Oct 2. doi: 10.1007/s00192-018-3772-6. [Epub ahead of print]

PMID:
30280203
3.

Perioperative Management of Women Undergoing Risk-reducing Surgery for Hereditary Breast and Ovarian Cancer.

AlHilli MM, Al-Hilli Z.

J Minim Invasive Gynecol. 2019 Feb;26(2):253-265. doi: 10.1016/j.jmig.2018.09.767. Epub 2018 Sep 19. Review.

PMID:
30240898
4.

Predicting non-home discharge in epithelial ovarian cancer patients: External validation of a predictive model.

Connor EV, Newlin EM, Jelovsek JE, AlHilli MM.

Gynecol Oncol. 2018 Oct;151(1):129-133. doi: 10.1016/j.ygyno.2018.08.011. Epub 2018 Aug 11.

PMID:
30107886
5.

Intestinal Surgery in Gynecologic Oncology: Are We Training for the Future?

Connor EV, Moulton LJ, Costales AB, Vargas R, Michener CM, AlHilli MM.

Int J Gynecol Cancer. 2018 Jun;28(5):983-988. doi: 10.1097/IGC.0000000000001250.

PMID:
29595760
6.

In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinoma.

AlHilli MM, Becker MA, Weroha SJ, Flatten KS, Hurley RM, Harrell MI, Oberg AL, Maurer MJ, Hawthorne KM, Hou X, Harrington SC, McKinstry S, Meng XW, Wilcoxen KM, Kalli KR, Swisher EM, Kaufmann SH, Haluska P.

Gynecol Oncol. 2016 Nov;143(2):379-388. doi: 10.1016/j.ygyno.2016.08.328. Epub 2016 Sep 8.

7.

Development of an Endometrial Ablation Model in New Zealand White Rabbits.

AlHilli MM, Brost BC, Marler R, Mariani A, Hopkins MR, Famuyide AO.

J Reprod Med. 2015 Jul-Aug;60(7-8):315-23.

PMID:
26380490
8.

Risk-adjusted outcomes in elderly endometrial cancer patients: implications of the contrasting impact of age on progression-free and cause-specific survival.

AlHilli MM, Bakkum-Gamez JN, Mariani A, Weaver AL, McGree ME, Keeney GL, Jatoi A, Dowdy SC, Podratz KC.

Gynecol Oncol. 2015 Jul;138(1):133-40. doi: 10.1016/j.ygyno.2015.04.010. Epub 2015 Apr 17.

PMID:
25895615
9.

Risk factors and indications for 30-day readmission after primary surgery for epithelial ovarian cancer.

AlHilli M, Langstraat C, Tran C, Martin J, Weaver A, McGree M, Mariani A, Cliby W, Bakkum-Gamez J.

Int J Gynecol Cancer. 2015 Feb;25(2):193-202. doi: 10.1097/IGC.0000000000000339.

10.

Distribution and volume of extrauterine disease in uterine serous carcinoma: is minimally invasive surgery a suitable approach?

Ayeni TA, AlHilli MM, Bakkum-Gamez JN, Mariani A, McGree ME, Weaver AL, Cliby WA, Keeney GL, Podratz KC, Dowdy SC.

Int J Gynecol Cancer. 2015 Jan;25(1):87-91. doi: 10.1097/IGC.0000000000000326.

PMID:
25474625
11.

Preoperative selection of endometrial cancer patients at low risk for lymph node metastases: useful criteria for enrollment in clinical trials.

AlHilli MM, Mariani A.

J Gynecol Oncol. 2014 Oct;25(4):267-9. doi: 10.3802/jgo.2014.25.4.267. No abstract available.

12.

Risk-scoring models for individualized prediction of overall survival in low-grade and high-grade endometrial cancer.

AlHilli MM, Mariani A, Bakkum-Gamez JN, Dowdy SC, Weaver AL, Peethambaram PP, Keeney GL, Cliby WA, Podratz KC.

Gynecol Oncol. 2014 Jun;133(3):485-93. doi: 10.1016/j.ygyno.2014.03.567. Epub 2014 Mar 29.

13.

Tumorgrafts as in vivo surrogates for women with ovarian cancer.

Weroha SJ, Becker MA, Enderica-Gonzalez S, Harrington SC, Oberg AL, Maurer MJ, Perkins SE, AlHilli M, Butler KA, McKinstry S, Fink S, Jenkins RB, Hou X, Kalli KR, Goodman KM, Sarkaria JN, Karlan BY, Kumar A, Kaufmann SH, Hartmann LC, Haluska P.

Clin Cancer Res. 2014 Mar 1;20(5):1288-97. doi: 10.1158/1078-0432.CCR-13-2611. Epub 2014 Jan 7.

14.

Use of computed tomography in the diagnosis of bowel complications after gynecologic surgery.

AlHilli MM, El-Nashar SA, Garrett AT, Weaver AL, Famuyide AO.

Obstet Gynecol. 2013 Dec;122(6):1255-62. doi: 10.1097/AOG.0000000000000014.

PMID:
24201687
15.

Risk-scoring system for the individualized prediction of lymphatic dissemination in patients with endometrioid endometrial cancer.

AlHilli MM, Podratz KC, Dowdy SC, Bakkum-Gamez JN, Weaver AL, McGree ME, Keeney GL, Cliby WA, Mariani A.

Gynecol Oncol. 2013 Oct;131(1):103-8. doi: 10.1016/j.ygyno.2013.06.037. Epub 2013 Jul 9.

PMID:
23845691
16.

Risk-scoring model for prediction of non-home discharge in epithelial ovarian cancer patients.

AlHilli MM, Tran CW, Langstraat CL, Martin JR, Weaver AL, McGree ME, Mariani A, Cliby WA, Bakkum-Gamez JN.

J Am Coll Surg. 2013 Sep;217(3):507-15. doi: 10.1016/j.jamcollsurg.2013.04.036. Epub 2013 Jun 29. Erratum in: J Am Coll Surg. 2017 Sep;225(3):453.

17.

The role of para-aortic lymphadenectomy in endometrial cancer.

AlHilli MM, Mariani A.

Int J Clin Oncol. 2013 Apr;18(2):193-9. doi: 10.1007/s10147-013-0528-7. Epub 2013 Feb 15. Review.

PMID:
23412768
18.

Long-term outcomes after intrauterine morcellation vs hysteroscopic resection of endometrial polyps.

AlHilli MM, Nixon KE, Hopkins MR, Weaver AL, Laughlin-Tommaso SK, Famuyide AO.

J Minim Invasive Gynecol. 2013 Mar-Apr;20(2):215-21. doi: 10.1016/j.jmig.2012.10.013. Epub 2013 Jan 5.

PMID:
23295201
19.

Uterine ultrasound findings after radiofrequency endometrial ablation: correlation with symptoms.

Alhilli MM, Wall DJ, Brown DL, Weaver AL, Hopkins MR, Famuyide AO.

Ultrasound Q. 2012 Dec;28(4):261-8. doi: 10.1097/RUQ.0b013e318276653b.

PMID:
23149510
20.

Impact of tubal ligation on routes of dissemination and overall survival in uterine serous carcinoma.

Ayeni TA, Bakkum-Gamez JN, Mariani A, McGree ME, Weaver AL, AlHilli MM, Martin JR, Keeney GL, Dowdy SC, Podratz KC.

Gynecol Oncol. 2013 Jan;128(1):71-76. doi: 10.1016/j.ygyno.2012.10.025. Epub 2012 Nov 2.

PMID:
23127971
21.

Preoperative biopsy and intraoperative tumor diameter predict lymph node dissemination in endometrial cancer.

AlHilli MM, Podratz KC, Dowdy SC, Bakkum-Gamez JN, Weaver AL, McGree ME, Kumar S, Keeney GL, Cliby WA, Mariani A.

Gynecol Oncol. 2013 Feb;128(2):294-9. doi: 10.1016/j.ygyno.2012.10.009. Epub 2012 Oct 17.

PMID:
23085458
22.

Incidence and factors associated with synchronous ovarian and endometrial cancer: a population-based case-control study.

AlHilli MM, Dowdy SC, Weaver AL, St Sauver JL, Keeney GL, Mariani A, Podratz KC, Bakkum-Gamez JN.

Gynecol Oncol. 2012 Apr;125(1):109-13. doi: 10.1016/j.ygyno.2011.12.444. Epub 2011 Dec 28.

23.

Aromatase inhibitors in the treatment of recurrent ovarian granulosa cell tumors: brief report and review of the literature.

Alhilli MM, Long HJ, Podratz KC, Bakkum-Gamez JN.

J Obstet Gynaecol Res. 2012 Jan;38(1):340-4. doi: 10.1111/j.1447-0756.2011.01698.x. Epub 2011 Dec 5. Review.

PMID:
22136798
24.

Endometrial cancer after endometrial ablation: systematic review of medical literature.

AlHilli MM, Hopkins MR, Famuyide AO.

J Minim Invasive Gynecol. 2011 May-Jun;18(3):393-400. doi: 10.1016/j.jmig.2011.02.004. Review.

PMID:
21545966

Supplemental Content

Loading ...
Support Center